TXN and cancer: To further investigate the effect of a dysregulated Txn system in pancreatic neoplasia in the context of mutant Kras, we used the TxnR inhibitor auranofin [28] in human pancreatic ductal and cancer cell lines in vitro to determine how oxidation of the Txn system affects ERK and AKT phosphorylation (Figure 3).